Elanco Animal Health Incorporated
NYSE:ELANDrug Manufacturers - Specialty & Generic
-$0.84 today
- Market cap
- $13.35B
- Beta
- 1.70
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.49
Volume 5.78M
Average 6.04M
ELAN Total Non-current Assets
All assets not expected to be converted to cash within one year.
Elanco Animal Health IncorporatedNYSE: ELAN
Total Non-current Assets · Q3 FY2026 · quarter ended Sep 2026
Total non-current assets falls 4.4% from a year ago
Total non-current assets stood at $9.61B at the end of Q3 FY2026, down 4.4% from a year earlier and down 1.5% from the prior quarter. Over 3 fiscal years it compounded at -6.8% a year.
Context
- Total non-current assets amounted to 72.1% of total assets at the end of Q3 FY2026, down 2.2 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -4.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 9.9B USD
- Year-over-year change
- +5.3%
- 4-year CAGR
- -6.9%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.9B | +5.3% |
| FY2024 | 2024-12-31 | 9.4B | -14.2% |
| FY2023 | 2023-12-31 | 10.96B | -10.3% |
| FY2022 | 2022-12-31 | 12.21B | -7.5% |
| FY2021 | 2021-12-31 | 13.2B | — |
Total Non-current Assets vs competitors
How ELAN compares with its peers on the latest reported figures
- ELAN's Sep 2026 total non-current assets of $9.61B is the 2nd highest of the 6 companies compared; the peer median is $2.72B.
- Its year-over-year change of -4.4% is the 5th highest of 6, against a peer median of +1.9%.
- Total non-current assets amounts to 72.1% of total assets for ELAN, versus a peer median of 59.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $93.12B | +15.7% | +8.3% | 71.7% | |
| Sep 2026 | $9.61B | -4.4% | -6.8% | 72.1% | |
| Jun 2026 | $8.72B | +1.9% | +5.4% | 57.8% | |
| Aug 2026 | $2.72B | -4.7% | -11.6% | 82.4% | |
| Sep 2026 | $2.21B | +11.5% | +6.9% | 59.5% | |
| Mar 2026 | $551.05M | +1.8% | +14.6% | 38.1% | |
| Peer median (excluding ELAN) | $2.72B | +1.9% | +6.9% | 59.5% | |
Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 638M | 345M | 352M | 468M | 545M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.03B | 1B | 1.01B | 886M | 940M |
| Inventory | 1.37B | 1.54B | 1.74B | 1.57B | 1.74B |
| Other Current Assets | 0 | 394M | 310M | 287M | 236M |
| Total Current Assets | 3.27B | 3.28B | 3.41B | 3.22B | 3.46B |
| Property, Plant & Equipment (Net) | 1.06B | 999M | 1.03B | 993M | 1.41B |
| Goodwill | 6.17B | 5.99B | 5.09B | 4.41B | 4.78B |
| Intangible Assets | 5.59B | 4.84B | 4.49B | 3.68B | 3.41B |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 390M | 378M | 341M | 311M | 304M |
| Total Non-current Assets | 13.2B | 12.21B | 10.96B | 9.4B | 9.9B |
| Total Assets | 16.48B | 15.49B | 14.36B | 12.61B | 13.36B |
| Account Payables | 416M | 390M | 270M | 296M | 368M |
| Short-term Debt | 294M | 388M | 38M | 44M | 74M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 937M | 924M | 933M | 975M | 1.16B |
| Total Current Liabilities | 1.65B | 1.7B | 1.24B | 1.32B | 1.6B |
| Long-term Debt | 6.03B | 5.45B | 5.74B | 4.28B | 3.94B |
| Deferred Tax Liabilities | 765M | 662M | 567M | 449M | 382M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 533M | 390M | 595M | 477M | 889M |
| Total Non-current Liabilities | 7.32B | 6.5B | 6.9B | 5.2B | 5.21B |
| Total Liabilities | 8.97B | 8.2B | 8.14B | 6.52B | 6.81B |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (979M) | (1.06B) | (2.29B) | (1.95B) | (2.18B) |
| Accumulated OCI | (209M) | (392M) | (266M) | (771M) | (141M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 7.51B | 7.29B | 6.22B | 6.1B | 6.55B |
| Total Debt | 6.32B | 5.84B | 5.77B | 4.32B | 4.02B |
| Net Debt | 5.68B | 5.49B | 5.42B | 3.85B | 3.47B |
Elanco Animal Health Incorporated
NYSE:ELAN
Intrinsic Alpha fair value
Locked
Current Price
$26.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.